Where Will Hershey Stock Be In 1 Year?
Chocolate stocks used to be the epitome of sleepy stability,…
Buy
61
CRL Quote, Financials, Valuation and Earnings
Last price:
$157.43
Seasonality move
:
2.86%
Day range:
$152.84 - $158.38
52-week range:
$91.86 - $254.15
Dividend yield:
0%
P/E ratio:
913.13x
P/S ratio:
2.01x
P/B ratio:
2.42x
Volume:
637.2K
Avg. volume:
851.9K
1-year change:
-21.83%
Market cap:
$7.7B
Revenue:
$4B
EPS (TTM):
-$0.65
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CRL
Charles River Laboratories International
|
$984.7M | $2.48 | -4.1% | 42.66% | $156.14 |
|
DVA
DaVita
|
$3.4B | $2.76 | 5.28% | 10.44% | $159.15 |
|
INCY
Incyte
|
$1.1B | $1.40 | 10.06% | 39.82% | $75.15 |
|
LLY
Eli Lilly and
|
$14.4B | $5.56 | 27.41% | 69.64% | $951.98 |
|
UFPT
UFP Technologies
|
$151.6M | $2.25 | 37.56% | 28.57% | $311.00 |
|
UNH
UnitedHealth Group
|
$111.7B | $4.90 | 13.15% | 11% | $385.25 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CRL
Charles River Laboratories International
|
$157.49 | $156.14 | $7.7B | 913.13x | $0.00 | 0% | 2.01x |
|
DVA
DaVita
|
$146.71 | $159.15 | $11.1B | 14.54x | $0.00 | 0% | 0.96x |
|
INCY
Incyte
|
$68.73 | $75.15 | $13.3B | 214.78x | $0.00 | 0% | 3.19x |
|
LLY
Eli Lilly and
|
$775.90 | $951.98 | $696.6B | 63.13x | $1.50 | 0.72% | 14.30x |
|
UFPT
UFP Technologies
|
$252.36 | $311.00 | $1.9B | 30.89x | $0.00 | 0% | 3.59x |
|
UNH
UnitedHealth Group
|
$326.14 | $385.25 | $295.9B | 13.66x | $2.21 | 2.61% | 0.74x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CRL
Charles River Laboratories International
|
44.01% | 1.972 | 33.75% | 0.94x |
|
DVA
DaVita
|
102.82% | 1.646 | 70.83% | 1.12x |
|
INCY
Incyte
|
-- | 1.205 | -- | 1.88x |
|
LLY
Eli Lilly and
|
70.96% | -0.134 | 5.19% | 0.57x |
|
UFPT
UFP Technologies
|
33.63% | 3.051 | 11.76% | 1.39x |
|
UNH
UnitedHealth Group
|
46.1% | -0.007 | 16.7% | 0.77x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CRL
Charles River Laboratories International
|
$317.7M | $74.7M | -0.52% | -0.87% | 6.49% | $112.4M |
|
DVA
DaVita
|
$983.9M | $433.3M | 7.42% | 38.96% | 13.07% | $36.8M |
|
INCY
Incyte
|
$979.7M | $216.7M | 0.57% | 0.57% | 22.31% | $262.9M |
|
LLY
Eli Lilly and
|
$10.5B | $5.4B | 24.21% | 78.25% | 29.07% | -$1.6B |
|
UFPT
UFP Technologies
|
$42.2M | $23.4M | 13.85% | 19.38% | 15.59% | $11M |
|
UNH
UnitedHealth Group
|
$23.8B | $9.1B | 12.37% | 21.74% | 8.31% | $4.6B |
Charles River Laboratories International vs. Competitors
-
Which has Higher Returns CRL or DVA?
DaVita has a net margin of 2.59% compared to Charles River Laboratories International's net margin of 5.05%. Charles River Laboratories International's return on equity of -0.87% beat DaVita's return on equity of 38.96%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International32.28% $0.50 $5.8B DVADaVita30.52% $2.00 $11.4B -
What do Analysts Say About CRL or DVA?
Charles River Laboratories International has a consensus price target of $156.14, signalling downside risk potential of -0.86%. On the other hand DaVita has an analysts' consensus of $159.15 which suggests that it could grow by 8.48%. Given that DaVita has higher upside potential than Charles River Laboratories International, analysts believe DaVita is more attractive than Charles River Laboratories International.
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International4 14 1 DVADaVita1 8 0 -
Is CRL or DVA More Risky?
Charles River Laboratories International has a beta of 1.495, which suggesting that the stock is 49.517% more volatile than S&P 500. In comparison DaVita has a beta of 1.106, suggesting its more volatile than the S&P 500 by 10.596%.
-
Which is a Better Dividend Stock CRL or DVA?
Charles River Laboratories International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DaVita offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Charles River Laboratories International pays -- of its earnings as a dividend. DaVita pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRL or DVA?
Charles River Laboratories International quarterly revenues are $984.2M, which are smaller than DaVita quarterly revenues of $3.2B. Charles River Laboratories International's net income of $25.5M is lower than DaVita's net income of $162.9M. Notably, Charles River Laboratories International's price-to-earnings ratio is 913.13x while DaVita's PE ratio is 14.54x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International is 2.01x versus 0.96x for DaVita. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International2.01x 913.13x $984.2M $25.5M DVADaVita0.96x 14.54x $3.2B $162.9M
-
Which has Higher Returns CRL or INCY?
Incyte has a net margin of 2.59% compared to Charles River Laboratories International's net margin of 15.03%. Charles River Laboratories International's return on equity of -0.87% beat Incyte's return on equity of 0.57%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International32.28% $0.50 $5.8B INCYIncyte93.05% $0.80 $3.7B -
What do Analysts Say About CRL or INCY?
Charles River Laboratories International has a consensus price target of $156.14, signalling downside risk potential of -0.86%. On the other hand Incyte has an analysts' consensus of $75.15 which suggests that it could grow by 9.33%. Given that Incyte has higher upside potential than Charles River Laboratories International, analysts believe Incyte is more attractive than Charles River Laboratories International.
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International4 14 1 INCYIncyte9 15 1 -
Is CRL or INCY More Risky?
Charles River Laboratories International has a beta of 1.495, which suggesting that the stock is 49.517% more volatile than S&P 500. In comparison Incyte has a beta of 0.679, suggesting its less volatile than the S&P 500 by 32.054%.
-
Which is a Better Dividend Stock CRL or INCY?
Charles River Laboratories International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Incyte offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Charles River Laboratories International pays -- of its earnings as a dividend. Incyte pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRL or INCY?
Charles River Laboratories International quarterly revenues are $984.2M, which are smaller than Incyte quarterly revenues of $1.1B. Charles River Laboratories International's net income of $25.5M is lower than Incyte's net income of $158.2M. Notably, Charles River Laboratories International's price-to-earnings ratio is 913.13x while Incyte's PE ratio is 214.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International is 2.01x versus 3.19x for Incyte. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International2.01x 913.13x $984.2M $25.5M INCYIncyte3.19x 214.78x $1.1B $158.2M
-
Which has Higher Returns CRL or LLY?
Eli Lilly and has a net margin of 2.59% compared to Charles River Laboratories International's net margin of 21.68%. Charles River Laboratories International's return on equity of -0.87% beat Eli Lilly and's return on equity of 78.25%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International32.28% $0.50 $5.8B LLYEli Lilly and82.53% $3.06 $54.4B -
What do Analysts Say About CRL or LLY?
Charles River Laboratories International has a consensus price target of $156.14, signalling downside risk potential of -0.86%. On the other hand Eli Lilly and has an analysts' consensus of $951.98 which suggests that it could grow by 22.69%. Given that Eli Lilly and has higher upside potential than Charles River Laboratories International, analysts believe Eli Lilly and is more attractive than Charles River Laboratories International.
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International4 14 1 LLYEli Lilly and17 4 1 -
Is CRL or LLY More Risky?
Charles River Laboratories International has a beta of 1.495, which suggesting that the stock is 49.517% more volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.
-
Which is a Better Dividend Stock CRL or LLY?
Charles River Laboratories International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.72% to investors and pays a quarterly dividend of $1.50 per share. Charles River Laboratories International pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRL or LLY?
Charles River Laboratories International quarterly revenues are $984.2M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Charles River Laboratories International's net income of $25.5M is lower than Eli Lilly and's net income of $2.8B. Notably, Charles River Laboratories International's price-to-earnings ratio is 913.13x while Eli Lilly and's PE ratio is 63.13x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International is 2.01x versus 14.30x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International2.01x 913.13x $984.2M $25.5M LLYEli Lilly and14.30x 63.13x $12.7B $2.8B
-
Which has Higher Returns CRL or UFPT?
UFP Technologies has a net margin of 2.59% compared to Charles River Laboratories International's net margin of 11.6%. Charles River Laboratories International's return on equity of -0.87% beat UFP Technologies's return on equity of 19.38%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International32.28% $0.50 $5.8B UFPTUFP Technologies28.45% $2.21 $543.4M -
What do Analysts Say About CRL or UFPT?
Charles River Laboratories International has a consensus price target of $156.14, signalling downside risk potential of -0.86%. On the other hand UFP Technologies has an analysts' consensus of $311.00 which suggests that it could grow by 23.24%. Given that UFP Technologies has higher upside potential than Charles River Laboratories International, analysts believe UFP Technologies is more attractive than Charles River Laboratories International.
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International4 14 1 UFPTUFP Technologies1 2 0 -
Is CRL or UFPT More Risky?
Charles River Laboratories International has a beta of 1.495, which suggesting that the stock is 49.517% more volatile than S&P 500. In comparison UFP Technologies has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.208%.
-
Which is a Better Dividend Stock CRL or UFPT?
Charles River Laboratories International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UFP Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Charles River Laboratories International pays -- of its earnings as a dividend. UFP Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios CRL or UFPT?
Charles River Laboratories International quarterly revenues are $984.2M, which are larger than UFP Technologies quarterly revenues of $148.1M. Charles River Laboratories International's net income of $25.5M is higher than UFP Technologies's net income of $17.2M. Notably, Charles River Laboratories International's price-to-earnings ratio is 913.13x while UFP Technologies's PE ratio is 30.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International is 2.01x versus 3.59x for UFP Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International2.01x 913.13x $984.2M $25.5M UFPTUFP Technologies3.59x 30.89x $148.1M $17.2M
-
Which has Higher Returns CRL or UNH?
UnitedHealth Group has a net margin of 2.59% compared to Charles River Laboratories International's net margin of 5.74%. Charles River Laboratories International's return on equity of -0.87% beat UnitedHealth Group's return on equity of 21.74%.
Company Gross Margin Earnings Per Share Invested Capital CRLCharles River Laboratories International32.28% $0.50 $5.8B UNHUnitedHealth Group21.7% $6.85 $186.4B -
What do Analysts Say About CRL or UNH?
Charles River Laboratories International has a consensus price target of $156.14, signalling downside risk potential of -0.86%. On the other hand UnitedHealth Group has an analysts' consensus of $385.25 which suggests that it could grow by 18.13%. Given that UnitedHealth Group has higher upside potential than Charles River Laboratories International, analysts believe UnitedHealth Group is more attractive than Charles River Laboratories International.
Company Buy Ratings Hold Ratings Sell Ratings CRLCharles River Laboratories International4 14 1 UNHUnitedHealth Group13 6 1 -
Is CRL or UNH More Risky?
Charles River Laboratories International has a beta of 1.495, which suggesting that the stock is 49.517% more volatile than S&P 500. In comparison UnitedHealth Group has a beta of 0.449, suggesting its less volatile than the S&P 500 by 55.115%.
-
Which is a Better Dividend Stock CRL or UNH?
Charles River Laboratories International has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. UnitedHealth Group offers a yield of 2.61% to investors and pays a quarterly dividend of $2.21 per share. Charles River Laboratories International pays -- of its earnings as a dividend. UnitedHealth Group pays out 52.29% of its earnings as a dividend. UnitedHealth Group's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CRL or UNH?
Charles River Laboratories International quarterly revenues are $984.2M, which are smaller than UnitedHealth Group quarterly revenues of $109.6B. Charles River Laboratories International's net income of $25.5M is lower than UnitedHealth Group's net income of $6.3B. Notably, Charles River Laboratories International's price-to-earnings ratio is 913.13x while UnitedHealth Group's PE ratio is 13.66x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Charles River Laboratories International is 2.01x versus 0.74x for UnitedHealth Group. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CRLCharles River Laboratories International2.01x 913.13x $984.2M $25.5M UNHUnitedHealth Group0.74x 13.66x $109.6B $6.3B
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will KNOT Stock Be In 1 Year?
In the case of KNOT Offshore Partners (KNOP), most headlines…
Why Is Goldman Sachs Stock Up So Much?
Investment banking giant Goldman Sachs (NYSE:GS) has sharply outperformed the…
Stock Ideas
Buy
60
Is NVDA Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 52x
Buy
60
Is MSFT Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 42x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Alerts
Buy
65
AEVA alert for Jul 3
Aeva Technologies [AEVA] is up 7.78% over the past day.
Sell
42
PRGS alert for Jul 3
Progress Software [PRGS] is down 2.94% over the past day.
Buy
60
NAIL alert for Jul 3
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 3.1% over the past day.
